Positive Phase IIIb trial results for savolitinib in lung cancer

Chinese biopharma Hutchmed (HKEX:13; AIM: HCM) today announced positive results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (MET) exon 14 skipping alteration non-small cell lung cancer (NSCLC).

The data were presented during the  IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC ), which is taking place in Singapore, and add to strong results of savolitinib in the treatment of adults with primary immune thrombocytopenia (ITP) that were announced last month.

Hutchmed reported initial efficacy and safety data from the first-line cohort of a confirmatory Phase IIIb trial conducted in China of savolitinib as a monotherapy in patients with NSCLC MET exon 14 skipping alterations. At data cut-off date of April 30, 2023, among the 84 patients in the tumor response evaluable set (TRES), objective response rate (ORR) was 60.7% (95% Confidence Interval (CI): 49.5% to 71.2%) and disease control rate (DCR) was 95.2% (95% CI: 88.3% to 98.7%), as assessed by an independent review committee.